Abstract
BackgroundKnowledge about COVID-19 infections is expanding, although knowledge about the disease course and antibody formation in patients with an auto-immune disease or immunodeficiency is not fully unraveled yet. It could be hypothesized that immunodeficient patients, due to immunosuppressive drugs or their disease, have a more severe disease course due to their immunocompromised state. However, it could also be hypothesized that some of the immunosuppressive drugs protect against a hyperinflammatory state. MethodsWe collected data on the incidence of COVID-19, disease course and SARS-CoV-2 antibody formation in COVID-19 positive patients in a cohort of patients (n = 4497) known at the Clinical Immunology outpatient clinic in a tertiary care hospital in the Netherlands. ResultsIn the first six months of the pandemic, 16 patients were identified with COVID-19, 14 by nasal swab PCR, and 2 patients by SARS-CoV-2 antibodies. Eight patients were admitted to the hospital. SARS-CoV-2 antibodies were measured in 8 patients and were detectable in all, including one patient on B-cell ablative therapy and one patient with Common Variable Immunodeficiency Disorder. ConclusionThis study indicates that the disease course differs among immunocompromised patients, independently of (dis)continuation of immunosuppressive drugs. Antibody production for SARS-CoV-2 in immunocompromised patients was shown. More research needs to be conducted to confirm these observations and guidelines regarding (dis)continuation of immunosuppressive drugs in COVID-19 positive immunocompromised patients should be developed.
Highlights
An infection with SARS-CoV-2 causes symptoms of the respiratory tract, but increasing evidence shows that almost every organ system can be involved [1,2]
It may be suggested that immunocompromised patients, either due to a primary immunodeficiency or a secondary immunodeficiency caused by the usage of immunosuppressive drugs, are at increased risk for infection and a more severe disease course with SARS-CoV-2 [6]
Our cohort consists of 4497 patients that are attending the outpatient clinic of the department of Clinical Immunology at the Erasmus University Medical Center (Rotterdam, the Netherlands)
Summary
An infection with SARS-CoV-2 causes symptoms of the respiratory tract, but increasing evidence shows that almost every organ system can be involved [1,2]. It may be suggested that immunocompromised patients, either due to a primary immunodeficiency or a secondary immunodeficiency caused by the usage of immunosuppressive drugs, are at increased risk for infection and a more severe disease course with SARS-CoV-2 [6]. To delineate the effect of an underlying immunological condition and/or immunosuppression on the course of COVID-19, we performed a descriptive study to investigate the incidence, disease course and SARS-CoV-2 antibody production in a cohort of patients with a primary or secondary immunodeficiency.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.